Yes, Imiquimod 5 % is approved for facial actinic keratoses. Apply a thin layer only to the lesions, following the prescribed schedule, and protect the surrounding skin from sun exposure.
Visible clearance often occurs within 8-12 weeks, but treatment may continue up to 16 weeks or until all warts are resolved. Individual response varies.
Imiquimod is classified as category B3 in the UK, indicating limited data. It should be used only if the potential benefit justifies any possible risk to the fetus, after a thorough discussion with a clinician.
Mild to moderate redness and soreness are expected. If the reaction is severe, spreads beyond the application site, or is accompanied by fever, stop treatment, gently wash the area, and seek medical advice promptly.
Apply sunscreen after the Imiquimod has fully dried, and only on surrounding skin, not directly on the treated lesion unless specifically instructed by your clinician.
Yes. Water can wash away the medication and increase irritation. Avoid swimming, hot tubs, or prolonged water exposure on treated areas for at least 12 hours after each application.
Imiquimod stimulates the immune system to clear viral lesions, whereas cryotherapy physically destroys tissue with extreme cold. Choice of therapy depends on lesion size, location, patient preference, and clinician recommendation.
Concurrent use of other irritant topicals (e.g., retinoids, salicylic acid) can increase skin irritation. Discuss any combination therapy with a healthcare provider before starting.
Return the empty tube to a pharmacy’s medication-return program or follow local NHS guidelines for safe disposal of prescription medicines. Do not flush it down the toilet.
Most patients experience temporary skin changes (redness, crusting) that resolve without scarring. Rarely, deep ulceration can lead to a scar; early reporting of severe reactions can help minimise this risk.
Imiquimod is a topical immune-response modifier classified under skin-care medicines. It is supplied as a 5 % formulation in a single-use tube. In the United Kingdom the product is prescription-only (POM) and regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Imiquimod works by stimulating the body's innate immune response to help clear abnormal skin cells. It is approved for the treatment of actinic keratosis, genital warts (condylomata acuminata) and superficial basal cell carcinoma.
Imiquimod binds to Toll-like receptor 7 (TLR-7) on immune cells in the skin. Activation of TLR-7 triggers the release of cytokines such as interferon-α, tumour necrosis factor-α and interleukins. These signaling molecules increase the activity of macrophages, natural-killer cells and other components of the immune system, leading to the destruction of virus-infected or dysplastic cells.
Because the drug is applied to the skin, systemic absorption is minimal, limiting systemic effects while providing a focused immune stimulus at the site of application.
These indications are supported by clinical trials conducted under MHRA oversight and are reflected in the product’s summary of product characteristics (SPC).
Imiquimod has been investigated for several off-label indications, including:
Disclaimer: Off-label use requires medical supervision, a risk-benefit assessment by a qualified clinician, and may not be covered by NHS prescribing policies.
These reactions usually diminish as treatment continues and are managed with moisturisers or temporary dose interruption under medical advice.
Imiquimod’s systemic absorption is low, so drug-drug interactions are uncommon. Caution is advised when used concurrently with:
The following are typical dosing schedules; exact instructions must be provided by a prescriber.
If a dose is missed, apply it as soon as remembered, provided it is within 12 hours of the usual time. Do not apply a double dose.
Signs of excessive local reaction (severe ulceration, extensive erythema) may indicate over-application. If this occurs, wash the area with mild soap and water, discontinue use, and seek medical advice. Systemic overdose is rare.
Most treatment courses are time-limited. If therapy is stopped early, lesions may recur; discuss follow-up options with a healthcare professional. No tapering is required because systemic exposure is minimal.
This article provides educational information about Imiquimod and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
